Royal Marsden Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (39)

2024

  1. Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma

    Clinical Genitourinary Cancer

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  3. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

2021

  1. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 643-654

  2. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

    Blood, Vol. 138, Núm. 18, pp. 1768-1773

2020

  1. Cabazitaxel in metastatic prostate cancer

    New England Journal of Medicine

  2. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

    Cancer Medicine, Vol. 9, Núm. 1, pp. 116-124

  3. Outcomes of COVID-19 in patients with CLL: a multicenter international experience

    Blood, Vol. 136, Núm. 10, pp. 1134-1143

2019

  1. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

    The Lancet Oncology, Vol. 20, Núm. 8, pp. 1109-1123

  2. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 3, pp. 420-435

2018

  1. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 1, pp. 87-100

  2. Reply to 'the St Gallen international expert consensus on the primary therapy of early breast cancer 2017: Te point of view of an international panel of experts in radiation oncology' by Kirova et al.

    Annals of Oncology

2017

  1. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1700-1712

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

    European Journal of Cancer, Vol. 56, pp. 85-92

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials

    The Lancet, Vol. 386, Núm. 10001, pp. 1353-1361

  2. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

    European Journal of Cancer

  3. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

    Breast Cancer Research, Vol. 17, Núm. 1